News & Analysis

AbbVie posts mixed results for Q1

2 May 2022 By Klavs Valters

Share

AbbVie Inc. reported its financial results for the first quarter before the market open on Friday in the US.

The biotechnology and pharmaceutical company reported revenue just shy of expectations at $13.538 billion (a 4.1% increase year-over-year) in Q1 vs. $13.662 billion expected.

Earnings per share reported at $3.16 per share (a 9.3% increase year-over-year) vs. $3.14 per share expected.

“This year is off to a strong start. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience,” Richard A. Gonzalez, Chairman and CEO of the company said in a press release following the first quarter results.

“Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year,” he added.

AbbVie Inc. chart

Shares of AbbVie fell by 6.03% on Friday, trading at $144.96 a share.

Here is how the stock has performed in the past year:

  • 1 Month -9.71%
  • 3 Month +50%
  • Year-to-date +48%
  • 1 Year +73%

AbbVie Inc. price targets

  • Morgan Stanley: $192
  • Wells Fargo: $165
  • Goldman Sachs: $140
  • Barclays: $174
  • UBS: $147

AbbVie Inc. is the 33rd largest company in the world with a market cap of $259.43 billion.

You can trade AbbVie Inc. (ABBV) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD.

Sources: AbbVie Inc., TradingView, CompaniesMarketCap

Disclaimer: Articles are from GO Markets analysts and contributors and are based on their independent analysis or personal experiences. Views, opinions or trading styles expressed are their own, and should not be taken as either representative of or shared by GO Markets. Advice, if any, is of a ‘general’ nature and not based on your personal objectives, financial situation or needs. Consider how appropriate the advice, if any, is to your objectives, financial situation and needs, before acting on the advice. If the advice relates to acquiring a particular financial product, you should obtain and consider the Product Disclosure Statement (PDS) and Financial Services Guide (FSG) for that product before making any decisions.